Organogenesis Holdings Inc. (ORGO) Guidance & Earnings Results
On 2026-05-07 Organogenesis Holdings Inc. lowered guidance: "FY2026 revenue guidance $270-310M (down 45-52%…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ORGOOrganogenesis Holdings Inc.Follow ORGO — free
—
Price chart with a free account
- Market cap
- 127.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 7 May 26 | Lowered | FY2026 revenue guidance $270-310M (down 45-52% YoY) · full year |
| 6 Nov 25 | Raised | Raises 2025 guidance · full year |
| 7 Aug 25 | Mixed | FY2025 adjusted EBITDA $31.1M-$61.9M; adjusted net income $5.5M-$28.3M; no revenue guidance provided. · full year |
Organogenesis Holdings Inc. — questions
- What guidance did Organogenesis Holdings Inc. give?
- On 2026-05-07: "FY2026 revenue guidance $270-310M (down 45-52% YoY)"
- When does Organogenesis Holdings Inc. report earnings?
- Organogenesis Holdings Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Organogenesis Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.